Seeking Alpha

Shares of Aveo Pharmaceuticals (AVEO) fall 17% premarket as the FDA asks the Oncologic Drugs...

Shares of Aveo Pharmaceuticals (AVEO) fall 17% premarket as the FDA asks the Oncologic Drugs Advisory Committee to help evaluate whether a single randomized trial is sufficient to warrant marketing approval for AVEO's renal cell carcinoma treatment tivozanib or whether further testing is necessary.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|